A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5910-5916

  Demetri, George D ^a   Casali, Paolo G ^b   Blay, Jean Yves ^c   Von Mehren, Margaret ^d   Morgan, Jeffrey A ^a   Bertulli, Rossella ^b   Ray Coquard, Isabelle ^c   Cassier, Philippe ^c   Davey, Monica ^d   Borghaei, Hossein ^d   Pink, Daniel ^e   Debiec Rychter, Maria ^f   Cheung, Wing ^g   Bailey, Stuart M ^g   Veronese, Maria Luisa ^g   Reichardt, Annette ^h   Fumagalli, Elena ^b   Reichardt, Peter ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CENTRE LÉON BÉRARD   (France)

^d FOX CHASE CANCER CENTER   (United States)

^e HELIOS Klinikum Bad Saarow   (Germany)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g NOVARTIS PHARMA AG   (Switzerland)

^h HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; DASATINIB; EVEROLIMUS; IMATINIB; MOTESANIB; NILOTINIB; SUNITINIB; UNCLASSIFIED DRUG; VEG 10003; VEG 100031;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLATULENCE; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MORNING DOSAGE; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SLEEP DISORDER; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG TOLERANCE; DRUG TOXICITY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349459886     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0542     Document Type: Article

References (31)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-1220 (Pubitemid 29480891)
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825
3. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008;3:557-586
4. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-632 (Pubitemid 351264358)
5. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480 (Pubitemid 34879334)
6. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134 (Pubitemid 39296599)
7. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774 (Pubitemid 46630941)
8. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005;6:249-251 (Pubitemid 40450717)
9. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338
10. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019 (Pubitemid 350236338)
11. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-664 (Pubitemid 46768841)
12. Antonescu CR , Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-4190 (Pubitemid 40791584)
13. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270-279 (Pubitemid 40431080)
14. Heinrich MC, Corless CL, Liegl B, et al. Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs). J Clin Oncol (Meeting Abstracts) 2007;25:10006.
15. Loughrey MB, Waring PM, Dobrovic A, et al. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin Cancer Res 2006;12:6205-6206 (Pubitemid 44703789)
16. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006;12:1743-1749
17. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008;14:5325-5331
18. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551 (Pubitemid 43882350)
19. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005;1754:3-13. (Pubitemid 41797682)
20. Prenen H, Guetens G, De Boeck G, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006;77:11-16
21. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704. (Pubitemid 44061372)
22. Dileo P, Bauer S, Van den Abbeele A, et al. Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST. Proc Am Soc Clin Oncol General Poster Session A 2006.
23. Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. Epub 2009. doi:10.1016.
24. Weisberg E, Catley L, Wright RD, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007;109:2112-2120 (Pubitemid 46348213)
25. White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP. Imatinib increases the intracellular concentration of nilotinib, whichmay explain the observed synergy between these drugs. Blood 2007;109:3609-3610
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of CancerNational Cancer Institute of the United States National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
27. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998;17:1103-1120 (Pubitemid 28221028)
28. National Cancer Institute. Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/reporting/ctc-v30.html 2006.
29. Yin OQP, Gallagher N, Li A, et al. Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy subjects. J Clin Pharmacol 2009, in press.
30. Bailey S, Neuenschwander B, Laird G, Branson M. A Bayesian case study in oncology Phase I combination dose-finding using logistic regression with covariates. J Biopharm Stat 2009;19:469-484
31. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008;27:2420-2439 (Pubitemid 351802902)